| Cat. No. | Species | Product Description | Structure | Purity | Feature |
|---|---|---|---|---|---|
| BAR-R52H3 | Rat | Rat BAFFR / TNFRSF13C Protein, His Tag |  |
|
|
| BAR-C52H4 | Cynomolgus | Cynomolgus BAFFR / TNFRSF13C Protein, His Tag |  |
|
|
| BAR-H52H3 | Human | Human BAFFR / TNFRSF13C Protein, His Tag |  |
|
|
| BAR-H82E3 | Human | Biotinylated Human BAFFR / TNFRSF13C Protein, His,Avitag™ (MALS verified) |  |
|
|
| BAR-H5258 | Human | Human BAFFR / TNFRSF13C Protein, Llama IgG2b Fc Tag, low endotoxin |  |
|
|
| BAR-H5257 | Human | Human BAFFR / TNFRSF13C Protein, Fc Tag |  |
|
|
| BAR-M5259 | Mouse | Mouse BAFFR / TNFRSF13C Protein, Fc Tag (HPLC verified) |  |
|
|
| BAR-M82F0 | Mouse | Biotinylated Mouse BAFFR / TNFRSF13C Protein, Fc,Avitag™ |  |
|
|
Immobilized Human BAFF, Fc Tag, active trimer (Cat. No. BAF-H5261) captured on CM5 chip via Anti-human IgG Fc antibodies surface can bind Human BAFFR, Llama IgG2b Fc Tag, low endotoxin (Cat. No. BAR-H5258) with an affinity constant of 44.5 nM as determined in a SPR assay (Biacore T200) (Routinely tested).
| Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
|---|---|---|---|---|---|
| Ianalumab | NOV-5; VAY-736 | Phase 3 Clinical | Morphosys Ag, Novartis Pharma Ag | Arthritis, Rheumatoid; Idiopathic Pulmonary Fibrosis; Sjogren's Syndrome; Lymphoma, Large B-Cell, Diffuse; Multiple Sclerosis; Lupus Erythematosus, Systemic; Hepatitis, Autoimmune; Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell; Pemphigus | Details |
This web search service is supported by Google Inc.
A-Z
